Taking a step back and looking at this situation,

Taking a step back and looking at this situation, it is easy to have a cautious attitude mostly because the SP is so far away from the drug's very near revenue potential and growing market opportunities. But, if I look at the fact that this is a one product company the has been in fund raising mode for 7-8 years with no revenue and on the OTC, the SP is somewhat explainable. In any other biotech, it would be natural to worry that some bad trial event might happen, a better drug gets to market first or their is a lack of any communication from the mgmt team, we don't have those worries. Cytodyn is updating us weekly, sometimes daily. We get to have a lot of words to dissect beyond actual meaning and the pressure is huge to get this SP to reflect the drug's value.

The growing list of indications is something most every drug does not experience - outside research is driving this growing list. Mgmt is not just throwing indications out there to create buzz for financing. It would be stupid to not publicize and pursue all opportunities for this drug.